Safety of Ceftriaxone in Paediatrics: a Systematic Review Protocol

Overview

Journal BMJ Open

Specialty General Medicine

Date 2017 Aug 23

PMID 28827252

Citations 3

Authors

Linan Zeng

Imti Choonara

Lingli Zhang

Song Xue

Zhe Chen

Miaomiao He

Affiliations

Soon will be listed here.

Abstract

Introduction: Ceftriaxone is widely used in children in the treatment of sepsis. However, concerns have been raised about the safety of ceftriaxone, especially in young children. The aim of this review is to systematically evaluate the safety of ceftriaxone in children of all age groups.

Methods And Analysis: MEDLINE, PubMed, Cochrane Central Register of Controlled Trials, EMBASE, CINAHL, International Pharmaceutical Abstracts and adverse drug reaction (ADR) monitoring systems will be systematically searched for randomised controlled trials (RCTs), cohort studies, case-control studies, cross-sectional studies, case series and case reports evaluating the safety of ceftriaxone in children. The Cochrane risk of bias tool, Newcastle-Ottawa and quality assessment tools developed by the National Institutes of Health will be used for quality assessment. Meta-analysis of the incidence of ADRs from RCTs and prospective studies will be done. Subgroup analyses will be performed for age and dosage regimen.

Ethics And Dissemination: Formal ethical approval is not required as no primary data are collected. This systematic review will be disseminated through a peer-reviewed publication and at conference meetings.

Prospero Registration Number: CRD42017055428.

Citing Articles

A Mitocentric View of the Main Bacterial and Parasitic Infectious Diseases in the Pediatric Population.

Romero-Cordero S, Kirwan R, Noguera-Julian A, Cardellach F, Fortuny C, Moren C Int J Mol Sci. 2021; 22(6).

PMID: 33806981 PMC: 8004694. DOI: 10.3390/ijms22063272.

A retrospective cross-sectional study to determine chirality status of registered medicines in Tanzania.

Mwamwitwa K, Kaibere R, Fimbo A, Sabitii W, Ntinginya N, Mmbaga B Sci Rep. 2020; 10(1):17834.

PMID: 33082444 PMC: 7575591. DOI: 10.1038/s41598-020-74932-x.

Safety of ceftriaxone in paediatrics: a systematic review.

Zeng L, Wang C, Jiang M, Chen K, Zhong H, Chen Z Arch Dis Child. 2020; 105(10):981-985.

PMID: 32144089 PMC: 7513262. DOI: 10.1136/archdischild-2019-317950.

References

Yao Y, Zhou R, Wang Y . Fatal adverse effects of injected ceftriaxone sodium in China. Pharmacoepidemiol Drug Saf. 2012; 21(11):1197-201. DOI: 10.1002/pds.3232. View

Girgis N, Sultan Y, Hammad O, Farid Z . Comparison of the efficacy, safety and cost of cefixime, ceftriaxone and aztreonam in the treatment of multidrug-resistant Salmonella typhi septicemia in children. Pediatr Infect Dis J. 1995; 14(7):603-5. DOI: 10.1097/00006454-199507000-00010. View

Donnelly P, Sutich R, Easton R, Adejumo O, Lee T, Logan L . Ceftriaxone-Associated Biliary and Cardiopulmonary Adverse Events in Neonates: A Systematic Review of the Literature. Paediatr Drugs. 2016; 19(1):21-34. DOI: 10.1007/s40272-016-0197-x. View

Northrop M, Agarwal H . Ceftriaxone-induced hemolytic anemia: case report and review of literature. J Pediatr Hematol Oncol. 2014; 37(1):e63-6. DOI: 10.1097/MPH.0000000000000181. View

Van Reempts P, Van Overmeire B, Mahieu L, Vanacker K . Clinical experience with ceftriaxone treatment in the neonate. Chemotherapy. 1995; 41(4):316-22. DOI: 10.1159/000239361. View

Richards D, Heel R, Brogden R, Speight T, Avery G . Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs. 1984; 27(6):469-527. DOI: 10.2165/00003495-198427060-00001. View

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009; 339:b2535. PMC: 2714657. DOI: 10.1136/bmj.b2535. View

Blumer J . Pharmacokinetics of ceftriaxone. Hosp Pract (Off Ed). 1991; 26 Suppl 5:7-13; discussion 52-4. DOI: 10.1080/21548331.1991.11707737. View

Egunsola O, Choonara I, Sammons H . Safety of lamotrigine in paediatrics: a systematic review. BMJ Open. 2015; 5(6):e007711. PMC: 4466618. DOI: 10.1136/bmjopen-2015-007711. View

10.

Rothman K, Lanes S, Sacks S . The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004; 13(8):519-23. DOI: 10.1002/pds.1001. View

11.

van Puijenbroek E, Egberts A, Meyboom R, Leufkens H . Different risks for NSAID-induced anaphylaxis. Ann Pharmacother. 2002; 36(1):24-9. DOI: 10.1345/aph.1A140. View

12.

Cleeland R, Squires E . Antimicrobial activity of ceftriaxone: a review. Am J Med. 1984; 77(4C):3-11. View

13.

Ferrajolo C, Verhamme K, Trifiro G, t Jong G, Picelli G, Giaquinto C . Antibiotic-Induced Liver Injury in Paediatric Outpatients: A Case-Control Study in Primary Care Databases. Drug Saf. 2016; 40(4):305-315. PMC: 5362651. DOI: 10.1007/s40264-016-0493-y. View

14.

McCracken Jr G, Siegel J, Threlkeld N, Thomas M . Ceftriaxone pharmacokinetics in newborn infants. Antimicrob Agents Chemother. 1983; 23(2):341-3. PMC: 186052. DOI: 10.1128/AAC.23.2.341. View

15.

Egunsola O, Choonara I, Sammons H . Safety of Levetiracetam in Paediatrics: A Systematic Review. PLoS One. 2016; 11(3):e0149686. PMC: 4773020. DOI: 10.1371/journal.pone.0149686. View

16.

Otunctemur A, Ozbek E, Polat E, Cekmen M, Dursun M, Cakir S . Increasing urinary calcium excretion after ceftriaxone and cephalothin therapy in adults: possible association with urolithiasis. Urolithiasis. 2013; 42(2):105-8. DOI: 10.1007/s00240-013-0627-y. View